-
公开(公告)号：US11713344B2
公开(公告)日：2023-08-01
申请号：US17410697
申请日：2021-08-24
申请人： DONG-A ST CO., LTD.
发明人： Jae-Sung Yang , Kyung-Seok Lee , Yu-Na Chae , Gye-Rim Baek , Tae-Hyoung Kim , Ill-Hun Jung , Chae-Lim Ryu , Weon-Bin Im
IPC分类号： C07K14/575 , A61P3/04 , A61P3/10 , A61K38/00
CPC分类号： C07K14/575 , A61P3/04 , A61P3/10 , A61K38/00
摘要： A novel peptide analog of acylated oxyntomodulin and its uses are disclosed. A pharmaceutical composition containing the novel peptide analog is useful and effective for preventing and treating obesity or overweightness, or diabetes accompanied by obesity and overweightness. The peptide analog and a composition containing the peptide analog are superior to those of wild-type oxyntomodulin in dual agonism on GLP-1 and glucagon receptors and longer in vivo half-life. A pharmaceutical composition containing the peptide analog is effective in the treatment of metabolic diseases such as obesity and diabetes mellitus.
-
公开(公告)号：US20220119473A1
公开(公告)日：2022-04-21
申请号：US17410697
申请日：2021-08-24
申请人： DONG-A ST CO., LTD.
发明人： Jae-Sung YANG , Kyung-Seok LEE , Yu-Na CHAE , Gye-Rim BAEK , Tae-Hyoung KIM , Ill-Hun JUNG , Chae-Lim RYU , Weon-Bin IM
IPC分类号： C07K14/575 , A61P3/04 , A61P3/10
摘要： A novel peptide analog of acylated oxyntomodulin and its uses are disclosed. A pharmaceutical composition containing the novel peptide analog is useful and effective for preventing and treating obesity or overweightness, or diabetes accompanied by obesity and overweightness. The peptide analog and a composition containing the peptide analog are superior to those of wild-type oxyntomodulin in dual agonism on GLP-1 and glucagon receptors and longer in vivo half-life. A pharmaceutical composition containing the peptide analog is effective in the treatment of metabolic diseases such as obesity and diabetes mellitus.
-
公开(公告)号：US20210113648A1
公开(公告)日：2021-04-22
申请号：US17039120
申请日：2020-09-30
申请人： DONG-A ST CO., LTD.
发明人： Soon-Hoe KIM , Mi-Won SON , Sang-Zin CHOI , Hye-Ju KIM , Ja-Young RYU , Sun-Yeou KIM
IPC分类号： A61K36/8945 , A23L33/105 , A23L2/52 , A61K9/00 , A61K9/08 , A61K9/20 , A61K9/48
摘要： Disclosed are a pharmaceutical composition and a health functional food for the prevention and treatment of diabetic peripheral neuropathy, comprising an herb extract of a mixture of 3.5:1 Dioscorea Rhizoma:Dioscorea nipponica (w/w). Having the ability to synergistically increase in vivo levels of nerve growth factor, compared to the extracts from the herbs alone or herb mixtures of other weight ratios, the mixed herb extract is effective for preventing the apoptosis of nerve cells and promoting nerve regeneration. Thus, it can be applied to pharmaceutical compositions and health functional foods preventive and curative of diabetic peripheral neuropathy.
-
公开(公告)号：US20210059956A1
公开(公告)日：2021-03-04
申请号：US16957774
申请日：2018-11-07
发明人： Sun-Woo JANG , Chang-Yell SHIN , Jeong-Soo KIM , Hae-Sun KIM , Kwang-Ho CHA , Hyun-Jung KIM , Masaoki GOTO
摘要： A percutaneous absorption preparation is disclosed. The percutaneous absorption preparation contains donepezil for treatment of dementia, wherein the preparation includes: (a) donepezil or its pharmaceutically acceptable salt as active component, (b) propylene glycol monocaprylate as solubilizer, and (c) styrene-isoprene-styrene block copolymer (“SIS”) as adhesive. The percutaneous absorption preparation has low skin irritation and high skin penetration.
-
公开(公告)号：US09822174B2
公开(公告)日：2017-11-21
申请号：US14893813
申请日：2014-05-30
发明人： Hyounmie Doh , Byong Moon Kim , Chae Young Kim , Sung-Hee Lee , Dong-Hyeon Kim , Yoo-jin Kim , Dongsop Lee , Kyung Mi Han , Dongsup Song , Eun-ee Jung , Jinseok Lee , Woo Jin Seung , Kyusang Hwang
IPC分类号： C07K16/22 , A61K39/395 , C07K16/30 , A61K39/00
CPC分类号： C07K16/22 , A61K39/3955 , A61K2039/505 , C07K16/30 , C07K2317/24 , C07K2317/33 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/76
摘要： A novel anti-vascular endothelial growth factor (VEGF) antibody having a strong binding affinity for VEGF and capable of inhibiting in vivo tumor growth and a composition for the treatment of cancer, containing the same. The antibody shows a remarkable binding property to human and mouse VEGF, suppresses the proliferation and permeability of a human umbilical vein endothelial cell (HUVEC) and inhibits tumor growth, and thus can be useful as an antibody for the treatment of cancer.
-
16.发明申请METHOD FOR PREPARING BENZAMIDE DERIVATIVE, NOVEL INTERMEDIATE USED IN PREPARATION OF BENZAMIDE, AND METHOD FOR PREPARING NOVEL INTERMEDIATE 有权制备苯甲酰衍生物的方法，用于制备苯甲酰胺的新型中间体，以及制备新型中间体的方法公开(公告)号：US20160185751A1
公开(公告)日：2016-06-30
申请号：US14907267
申请日：2014-07-11
申请人： DONG-A ST CO., LTD
发明人： Woo Young KWAK , Kyung Seok LEE , Ullapu Punna REDDY , Soon Kyu Jung , Tae Sun PARK , Joong In LIM
IPC分类号： C07D401/06 , C07C57/145 , C07C59/255 , C07C57/15 , C07C55/14 , C07C59/265
CPC分类号： C07D401/06 , C07C55/14 , C07C57/145 , C07C57/15 , C07C59/255 , C07C59/265
摘要： The present invention relates to a method for preparing N-[[1-{3-(1,2,3-triazol-1-yl)propyl}piperidin-4-yl]methyl]-4-amino-5-chloro-2-methoxybenzamide, which is a novel benzamide derivative as a 5-HT4 receptor agonist, or a pharmaceutically acceptable salt thereof; to a novel intermediate capable of being used in the preparation of the compounds; and to a method for preparing the same. The preparation methods of the present invention can be useful for mass production since a low-priced reagent and intermediate are used and the number of reaction processes is decreased, thereby saving preparation costs and improving the yield.
摘要翻译： 本发明涉及制备N - [[1- {3-（1,2,3-三唑-1-基）丙基}哌啶-4-基]甲基] -4-氨基-5-氯 - 2-甲氧基苯甲酰胺，它是一种新的苯甲酰胺衍生物作为5-HT4受体激动剂，或其药学上可接受的盐; 涉及能够用于制备化合物的新型中间体; 以及其制备方法。 本发明的制备方法可以用于批量生产，因为使用低价试剂和中间体，并且反应过程的数量减少，从而节省了制备成本并提高了产率。
-
17.发明申请ANTI-VEGF ANTIBODY, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, DIAGNOSING OR TREATING CANCER OR ANGIOGENESIS-RELATED DISEASES, CONTAINING SAME 有权抗VEGF抗体和药物组合物，用于预防，诊断或治疗癌症或与血管发生相关的疾病公开(公告)号：US20160122426A1
公开(公告)日：2016-05-05
申请号：US14893813
申请日：2014-05-30
发明人： Hyounmie DOH , Byong Moon KIM , Chae Young KIM , Sung-Hee LEE , Dong-Hyeon KIM , Yoo-jin KIM , Dongsop LEE , Kyung Mi HAN , Dongsup SONG , Eun-ee JUNG , Jinseok LEE , Woo Jin SEUNG , Kyusang HWANG
IPC分类号： C07K16/22 , A61K39/395 , C07K16/30
CPC分类号： C07K16/22 , A61K39/3955 , A61K2039/505 , C07K16/30 , C07K2317/24 , C07K2317/33 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/76
摘要： A novel anti-vascular endothelial growth factor (VEGF) antibody having a strong binding affinity for VEGF and capable of inhibiting in vivo tumor growth and a composition for the treatment of cancer, containing the same. The antibody shows a remarkable binding property to human and mouse VEGF, suppresses the proliferation and permeability of a human umbilical vein endothelial cell (HUVEC) and inhibits tumor growth, and thus can be useful as an antibody for the treatment of cancer.
摘要翻译： 一种具有对VEGF具有强结合亲和力并能够抑制体内肿瘤生长的新型抗血管内皮生长因子（VEGF）抗体和含有该组合物的治疗癌症的组合物。 该抗体对人和小鼠VEGF显示出显着的结合性，抑制人脐静脉内皮细胞（HUVEC）的增殖和通透性并抑制肿瘤生长，因此可用作治疗癌症的抗体。
-
公开(公告)号：US12115159B2
公开(公告)日：2024-10-15
申请号：US17275555
申请日：2019-09-11
申请人： DONG-A ST CO., LTD.
发明人： Mi-Kyung Kim , Bo Ram Lee , Hansu Park , Seung Ho Lee , Yu Na Chae
IPC分类号： A61K31/506 , A23L33/10 , A61P1/06
CPC分类号： A61K31/506 , A23L33/10 , A61P1/06
摘要： The present invention pertains to a pharmaceutical composition for preventing or treating non-alcoholic fatty liver disease, the composition containing G protein coupled receptor 119 (GPR119) ligand as an active ingredient. The pharmaceutical composition according to the present invention exhibits the excellent effects of improving lipid metabolism, reducing fat accumulation in liver tissues, and preventing histological damage caused by inflammation and fibrosis in liver tissues, and can thus be useful in preventing or treating non-alcoholic fatty liver disease.
-
公开(公告)号：US20230201131A1
公开(公告)日：2023-06-29
申请号：US17924781
申请日：2021-05-12
发明人： Sun-Woo JANG , Chang-Yell SHIN , Hae-Sun KIM , Kwang-Ho CHA , Hyun-jung KIM , Sang-Min HYUN , Masaoki GOTO
IPC分类号： A61K9/70 , A61K31/445 , A61K47/16 , A61K47/20 , A61K47/22
CPC分类号： A61K9/7038 , A61K31/445 , A61K47/16 , A61K47/20 , A61K47/22
摘要： A percutaneous absorption preparation for the treatment of dementia wherein the drug-containing layer contains donepezil or a pharmaceutically acceptable salt thereof as an active ingredient and a stabilizer that is either (i) a mixture of a thiocyanate salt and a compound selected from the group consisting of tea catechin, (+)-catechin, epigallocatechin gallate, ascorbic acid, and isoascorbic acid, or (ii) a mixture of monothioglycerol and a compound selected from the group consisting of tea catechin, (+)-catechin, epigallocatechin gallate, and ascorbic acid is disclosed. The percutaneous absorption preparation meets the criteria of Procedure 1 and Procedure 2 of the U.S. Pharmacopoeia in short-term stress test (70° C. 48 hours storage), long-term accelerated test 1 (40° C. relative humidity 75% 1 month storage), and long-term accelerated test 2 (40° C. relative humidity 75% 3 months storage), and exhibits improved stability for long-term preservation.
-
公开(公告)号：US20230133381A1
公开(公告)日：2023-05-04
申请号：US16492780
申请日：2018-02-08
申请人： DONG-A ST CO., LTD.
发明人： Hyounmie DOH , Dongsop LEE , Hanyoung LEE , Yoojin KIM , Kyungmi HAN , Eunee JUNG , Donghyeon KIM , Eongsup SONG , Kum-Joo SHIN , Soyon WOO
摘要： The present invention relates to an antibody that specifically binds to death receptor 5 (DR5) and has a function of killing cancer cells. Specifically, provided are an anti-DR5 antibody or antigen-binding fragment thereof, and a use of the antibody or antigen-binding fragment for preventing or treating cancer. The present invention is characterized in that the anti-DR5 antibody or antigen-binding fragment thereof is improved in terms of affinity to DR5, stability, and an effect of killing cancer cells.
-
-
-
-
-
-
-
-
-
搜索结果
48 条记录 (耗时 0.022 秒)
